M&A deals by therapy area in Q4, 2019

16 January 2020

One deal skewed the picture in looking at the M&A activity by therapy area in the final quarter of 2019.

Looking at the upfront value of the deals reported on by The Pharma Letter that were announced in the three-month period, the biggest spend was in cardiovascular, with nearly double what was spent in the second-highest therapy area.

The $9.7 spent all stemmed from Swiss pharma giant Novartis’ (NOVN: VX) takeover of The Medicines Company (Nasdaq: MCDO) and its key novel siRNA candidate inclisiran, a biennial cholesterol-lowering drug now in Phase III testing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK